logo

AMGEN INC(NSDQ:AMGN)
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science''s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people''s lives.
# Employees: 16900
Address: One Amgen Center Drive,Thousand Oaks,CA,USA
Phone: 805 447-1000
Fax: 805 477-1010
Website: www.amgen.com
Email: investor.relations@amgen.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Kevin W. Sharer (Chmn.; Presi.; C.E.O.; Dir.)
Robert A. Bradway (Exec. V.P.; C.F.O.)
Michael A. Kelly (V.P.; Chief Acctg. Off.)
David Baltimore (Dir.)
Jerry D. Choate (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 1/25/2010
Mean EPS (Next Qtr): $1.15
Mean EPS (Year): $4.95
Mean Estimate(Long Term): $10.79
P/E Ratio(Based on EPS estimate): 11.420
Number of Estimates: 10
Shares Performance
Period AMGN Compare to S&P
YTD -2.16 % -19.04 %
4 Weeks 5.37 % 0.03 %
12 Weeks -4.16 % -10.75 %
Shares Information
Analyst Coverage: Y
Avg Volume: 6124900
Shares Outstanding: 1015M
Market Cap: $57.37B
52 Week High: $64.41
52 Week Low: $45.11
P/E Ratio: 11.580
PEG Ratio: 1.060
Split: On 11/22/1999 AMGN split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: 17.32 %
EPS Growth in Last Year: 23.14 %
Sales Growth in Last Quarter: 2.67 %
Sales Growth in Last Quarter: -1.63 %
Financials
Qtr Book Value: $2.51
Cash Flow/Share: $10.16
Change in Payout Ratio: 0.000
Price/Sales: 3.930
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia